Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 8, Issue 12, Pages 1985-1998Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656566.8.12.1985
Keywords
cardiovascular disease; insulin resistance; intima-media thickness; pioglitazone; Type 2 diabetes mellitus
Categories
Ask authors/readers for more resources
Pioglitazone, a member of the PIPAR-gamma agonist drug family, has been demonstrated to improve both metabolic and vascular insulin resistance when applied to patients with Type 2 diabetes mellitus. The drug is well tolerated with fluid retention and weight gain being the most frequently described side effects. The observed effects (e.g., improvements in glucose and lipid metabolism, improvements of enclothelial function and microcirculation, reduction of surrogate markers of atherosclerosis and inflammation and an improvement in hypertension) have made pioglitazone one of the frequently prescribed antidiabetic drugs in the US and Europe. Several trials have shown its potency to reduce carotid intima-media thickness, and outcome studies with pioglitazone have shown its potential to delay the progression of Type 2 diabetes and atherosclerosis and even reduce cardiovascular mortality. The purpose of this review is to provide an overview about recently published clinical results with pioglitazone. They underline the value of this drug when used alone or in combination with other antidiabetic drugs for a successful management of Type 2 diabetes mellitus.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available